Summary
Molbio Diagnostics IPO opens for subscription on August 10th, 2026 and closes on August 12th, 2026, with a price band of ₹768 to ₹807 per share.
This is a book-building IPO that will list on the NSE and BSE platforms on August 17th, 2026.
Molbio Diagnostics IPO is a book-building IPO which is to be listed on both BSE and NSE platforms. It is fixed to open on 10th August 2026 and close on 12th August 2026. The company is offering both a fresh issue and an offer for sale and has fixed its price band at ₹768 to ₹807.
The objective of this IPO is to establish a new R%D facility, Centre of Excellence, and connected offices. It also aims to purchase new plant, machinery, and equipment for its facilities, and other general corporate purposes.
Molbio Diagnostics IPO Key Details
The table below presents the essential details investors should know before applying for the Molbio Diagnostics IPO.
| IPO Open Date | 10 August 2026 |
| Close Date | 12 August 2026 |
| Face value | ₹1 per share |
| Price Band | ₹768 to ₹807 |
| IPO Lot Size | 18 shares |
| Fresh issue | _ |
| Offer for Sale | 91,66,000 |
| Type of issue | Book-building |
| Listing at | NSE, BSE |
| Total Issue Size (₹ Crore) | ₹940 approx |
| Minimum Investment | 1 lot or 18 shares |
Molbio Diagnostics IPO Timeline
Below is the complete schedule of events for the Molbio Diagnostics IPO.
| Bid Opening | 10 August 2026 |
| Bid Closing | 12 August 2026 |
| Tentative Allotment | 13 August 2026 |
| Initiation of Refunds | 14 August 2026 |
| Credit of Shares to Demat | 14 August 2026 |
| Tentative Listing Date | 17 August 2026 |
| UPI mandate closing date | 12 August 2026 |
Key Performance Indicators of Molbio Diagnostics IPO
These financial ratios highlight the company’s profitability, capital efficiency, and overall financial performance over the past three financial years.
| 31-03-2026 | 31-03-2025 | 31-03-2024 | |
| ROE (%) | 15.59 | 16.20 | 13.20 |
| ROCE (%) | 17.55 | 20.98 | 15.80 |
| Debt Equity (in times) | |||
| RoNW (%) | 14.55 | 15.23 | 12.62 |
| PAT Margin (%) | 11.28 | 13.48 | 9.94 |
| EBITDA margin (%) | 22.56 | 24.97 | 22.02 |
| Price to book | 9.55 |
Molbio Diagnostics IPO Financial Details
The Financial information of the Molbio Diagnostics IPO is as follows.
| FY 2025-2026 | FY 2024-2025 | FY 2023-2024 | |
| Revenue | 1,445.68 | 1,020.41 | 836.56 |
| Total Asset | 2,148.42 | 1,461.55 | 1,221.05 |
| Profit | 164.14 | 138.57 | 83.54 |
(Amount in ₹ Crores)
Molbio Diagnostics IPO Subscription Status
The subscription data is not available yet.
Bidding is open from 10:00 AM to 5:00 PM on public issue days.
Molbio Diagnostics IPO Grey Market Premium (GMP)
The current status of the Grey Market Premium for the Molbio Diagnostics IPO shows a GMP of ₹0. Therefore, according to the status, the IPO price displays an amount of ₹807.
| GMP Date | GMP | Est. Listing Price (cap price + GMP) | Est. Profit* | Last Updated |
|---|---|---|---|---|
| 06-08-2026 | ₹200 ▲ | ₹1007 (24.78%) | ₹3,600 | 6-Aug-2026 11:57 |
| 05-08-2026 | ₹170 ▲ | ₹977 (21.07%) | ₹3,060 | 5-Aug-2026 23:37 |
| 04-08-2026 | ₹0 ─ | ₹ (%) | 4-Aug-2026 12:00 |
GMP is the premium value of the share in the unofficial market before it opens for subscription.
Molbio Diagnostics IPO Reservation
The following table shows the distribution of shares reserved for retail investors, QIBs, and NIIs under the IPO.
| Investor Category | Offered No. of Shares |
| Market maker | |
| QIBs | Not more than 50% of the total issue |
| NIIs | Not less than 35% of the total issue |
| Retails | Not less than 15% of the total issue |
| Total |
Molbio Diagnostics IPO Lot Sizes
Investors can refer to the minimum and maximum investment requirements for each investor category as per the prescribed lot size.
| Application | Lot | Shares | Amount |
| Retail (Min) | 1 | 18 | ₹14,526 |
| Retail (Max) | 13 | 234 | ₹1,88,838 |
| S-HNI (Min) | 14 | 252 | ₹2,03,364 |
| S-HNI (Max) | 68 | 1,224 | ₹9,87,768 |
| B-HNI (Min) | 69 | 1,242 | ₹10,02,294 |
Molbio Diagnostics IPO Prospectus
Investors can access the offered prospectus for the Molbio Diagnostics IPO mentioned below.
About Molbio Diagnostics Ltd.
Molbio Diagnostics Ltd. is a global point-of-care diagnostics company that engages in research, development, manufacturing, and supply of rapid solutions for non-communicable and infectious diseases. They provide testing solutions for 30 diseases, including tuberculosis, COVID-19, HIV, and HPV.
The company has a wide domestic as well as international customer base, including hospitals, diagnostic laboratories, public healthcare programs, and research organisations. With the support of strong research and development, the company established itself as a leading innovator in molecular diagnostics.
Promoters:
- Sriram Natarajan
- Dr Chandrasekhar Bhaskaran Nair
- Sangeetha Sriram
- Shiva Sriram
- Sowmya Sriram
- Exxora Trading LLP
| Book Runner | Kotak Mahindra Capital Co. Ltd. IIFL Capital Services Ltd Jefferies India Pvt. Ltd. Motilal Owwal Investment Advisors Ltd. |
| Issue Registrar | Kfin Technologies Ltd. |
Purpose of Molbio Diagnostics IPO
The company intends to deploy the funds raised through this public issue toward specific operational and strategic goals, as detailed in the table below.
| Particulars | Amount in ₹ Crores |
| For establishing R&D facility, Centre of Excellence, and connected office spaces | 105.54 |
| For purchasing plant, equipment, and machinery | 72.28 |
| General Corporate Purpose | _ |
| Total | _ |
Molbio Diagnostics Ltd.- Strengths and benefits
- The company has a wide customer base catering to around 90 countries, including government and institutional customers.
- It developed a proprietary Truenat platform molecular diagnostic technology that is endorsed by the WHO.
- Through strategic acquisition and collaboration, it has expanded its healthcare portfolio.
Molbio Diagnostics Ltd- Risks and limitations
- It is a highly competitive market, including competition from both domestic and international participants.
- Disruption in the movement of the supply chain may hamper the operations and overall performance of the company.
- Any change in government policy or global event may impact the revenue and profitability of the company.
Molbio Diagnostics IPO Review
Molbio Diagnostics IPO is the IPO offering both fresh issue and offer for sale to the public. The subscription of the shares is fixed to open on August 10, 2026 and close on August 12, 2026. It provides an opportunity to invest in the emerging diagnostic industry. The company shows an improvement in its financial performance, including its revenue and profitability. However, investors must analyse the details thoroughly and check whether it aligns with their investment objective and risk appetite before investing.
Other recent IPO List
Explore the listing information of other currently active and upcoming public issues in India.
| Anawil Wire and Engineering IPO | Aegeus Technologies IPO |
| LAPL Automotive IPO | Optimystix Entertainment India IPO |
| Ardee Industries IPO | Technocraft Ventures IPO |
| Fusion Klassroom Edutech IPO | G.V Electricals IPO |
Molbio Diagnostics IPO FAQs
Molbio Diagnostics IPO is a book-building public issue opening from 10th to 12th August 2026 with a price band of ₹768–₹807 per share.
You can apply through your broker or bank using the ASBA facility or via any UPI-supported IPO application platform.
The IPO should be evaluated based on the company’s financial performance, valuation, industry outlook, and your investment objectives before investing.
The IPO opens for subscription on 10th August 2026.
The minimum application is 1 lot consisting of 18 shares.
The tentative basis of allotment is expected on 13th August 2026.
The shares are tentatively scheduled to be listed on the NSE and BSE on 17th August 2026.
